Anupam Rasayan India Limited has acquired a 43.3-48.2% equity stake in Bliss GVS Pharma Limited, a pharmaceutical formulations company, as per a BSE filing.
The total purchase consideration has been financed through a Rs 300 Crores term loan and a non-controlling non-voting equity instrument for the balance amount. This acquisition marks a significant expansion of Anupam Rasayan’s presence in the pharmaceutical sector.
The project involves the acquisition of a significant stake in Bliss GVS Pharma, which is engaged in the development, manufacturing, marketing, and export of a wide range of dosage forms.
Bliss GVS Pharma has a strong presence across regulated and semi-regulated international markets, particularly in Africa, Asia, and Latin America. The company is globally recognized for its leadership in suppositories and pessaries.
As part of the agreement, Anupam Rasayan will acquire a 43.3-48.2% equity stake in Bliss GVS Pharma, with an option to acquire additional shares through an open offer to public shareholders.
The acquisition is expected to strengthen Anupam Rasayan’s position in the pharmaceutical sector. The company’s managing director, Anand Desai, commented on the acquisition, stating that it is a strategic move to expand the company’s presence in the pharmaceutical sector.
The order adds to Anupam Rasayan’s growing portfolio of acquisitions in the pharmaceutical sector. The company has been expanding its presence in the sector through strategic acquisitions and partnerships. This acquisition is expected to drive long-term growth for Anupam Rasayan and strengthen its position as a leading player in the pharmaceutical sector.
This acquisition reinforces Anupam Rasayan’s position as a leading player in the pharmaceutical sector. The company’s strategic expansion into the pharmaceutical sector is expected to drive growth and increase its market share.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
